scispace - formally typeset
S

Silvana Müller

Researcher at Innsbruck Medical University

Publications -  73
Citations -  1628

Silvana Müller is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Ejection fraction & Myocardial infarction. The author has an hindex of 21, co-authored 73 publications receiving 1502 citations. Previous affiliations of Silvana Müller include Tokyo Medical University.

Papers
More filters
Journal ArticleDOI

Multislice computed tomography for detection of patients with aortic valve stenosis and quantification of severity.

TL;DR: Multislice computed tomography may provide an accurate, noninvasive imaging technique for detection of patients with AS and quantification of AVA in comparison to the accepted diagnostic standard transthoracic echocardiography.
Journal ArticleDOI

Transvenous Pacemaker Lead Removal Is Safe and Effective Even in Large Vegetations: An Analysis of 53 Cases of Pacemaker Lead Endocarditis

TL;DR: The aim of this study was to investigate whether transvenous lead removal is safe and effective in patients with lead vegetations greater than 1 cm in size.
Journal ArticleDOI

Sixty-Four Slice CT Evaluation of Aortic Stenosis Using Planimetry of the Aortic Valve Area

TL;DR: MDCT allows accurate planimetry of the aortic valve area in patients with aorti stenosis and in patients referred for 64-slice CT coronary angiography, concomitant aortIC stenosis can be identified and evaluated.
Journal ArticleDOI

Natriuretic Peptides as Markers of Mild Forms of Left Ventricular Dysfunction: Effects of Assays on Diagnostic Performance of Markers

TL;DR: The performance of BNP for the diagnosis of systolic or diastolic LVD is not affected by the assay used, whereas the performance of NT-proBNP for thediagnosis of isolated diastolics LVA is assay dependent.
Journal ArticleDOI

Prognosis and Risk Factors in Patients With Asymptomatic Aortic Stenosis and Their Modulation by Atorvastatin (20 mg)

TL;DR: TASS could demonstrate a poor clinical outcome in patients with asymptomatic calcified aortic stenosis which can be predicted by new risk factors such as strong AVC or increased plasma levels of CRP or NT-proBNP, but the study does not support the concept that treatment with a HMG-CoA reductase inhibitor (20 mg atorvastatin once daily) halts the progression of calcify aorta stenosis.